Disease X Act of 2023

This bill amends the Public Health Service Act to prioritize pandemic preparedness for unknown viral threats. It directs the Secretary to develop platform manufacturing technologies for rapid medical countermeasures and fund flexible research against high-risk respiratory viruses (including pathogen-agnostic approaches). The bill authorizes $40 million annually (2024-2028) for these specific purposes, requiring that products developed with this funding be substantially manufactured in the U.S. unless waived for public interest reasons. It directly affects federal health agencies managing pandemic response and U.S. manufacturers receiving these funds.